ライフサイエンスコーパス: membranous nephropathy

1 (PLA2R1) is the major autoantigen in primary membranous nephropathy.

2 lie the loss of podocyte barrier function in membranous nephropathy.

3 eymann nephritis (PHN), a rat model of human membranous nephropathy.

4 ce active Heymann nephritis (HN), a model of membranous nephropathy.

5 Heymann nephritis (HN), a rat model of human membranous nephropathy.

6 glomerulonephritis and less frequently with membranous nephropathy.

7 tients met the criteria for NSAID-associated membranous nephropathy.

8 AID intake should be sought in patients with membranous nephropathy.

9 A2R1) is the major autoantigen in idiopathic membranous nephropathy.

10 toantigen in 70% of patients with idiopathic membranous nephropathy.

11 y showed phospholipase A 2 receptor-negative membranous nephropathy.

12 he UPS depended on oxidative modification in membranous nephropathy.

13 imal-change disease and a low correlation in membranous nephropathy.

14 d human glomerular diseases, particularly in membranous nephropathy.

15 rtant advances regarding the pathogenesis of membranous nephropathy.

16 R) is the major target antigen in idiopathic membranous nephropathy.

17 R) are sensitive and specific for idiopathic membranous nephropathy.

18 dict response to treatment with rituximab in membranous nephropathy.

19 and segmental glomerulosclerosis (FSGS) and membranous nephropathy.

20 mmune deposits in glomeruli of patients with membranous nephropathy.

21 peutic intervention in patients with primary membranous nephropathy.

22 erlying disease and seems to be greatest for membranous nephropathy.

23 diseases, with highest induction observed in membranous nephropathy.

24 omerulonephritis, and severe skin lesions or membranous nephropathy.

25 Here, we describe a patient with recurrent membranous nephropathy 13 days after kidney transplantat

26 oliferative glomerulonephritis (GN), 18; and membranous nephropathy, 16.

27 Of 125 patients identified with early membranous nephropathy, 29 were taking NSAIDs at the tim

28 Idiopathic membranous nephropathy, a common form of the nephrotic s

29 n the prominent expression of FHR-5 in human membranous nephropathy, a disease in which complement ac

30 (18-75 years) with biopsy-proven idiopathic membranous nephropathy, a plasma creatinine concentratio

31 g a large cohort of patients with idiopathic membranous nephropathy according to a restrictive treatm

32 steroid-sensitive nephrotic syndrome or with membranous nephropathy after transplantation had low lev

33 However, in some patients with membranous nephropathy and crescents, the crescentic les

34 For the subset of patients with idiopathic membranous nephropathy and deteriorating excretory renal

35 n for end-stage renal disease resulting from membranous nephropathy and diabetic nephropathy.

36 In nephrotic diseases, such as membranous nephropathy and FSGS, persistent injury often

37 pressive therapy in patients with idiopathic membranous nephropathy and nephrotic syndrome.

38 rt of 117 Caucasian patients with idiopathic membranous nephropathy and nephrotic-range proteinuria u

39 Crescents are rare in primary membranous nephropathy and thus suggest another underlyi

40 and nephrotic syndrome (minimal change/FSGS, membranous nephropathy, and C3 glomerulopathies).

41 and fibrosis, IgA nephropathy and idiopathic membranous nephropathy, and kidney transplantation.

42 e glomerulonephritis and another patient had membranous nephropathy as the cause of end-stage renal d

43 been made in our understanding of idiopathic membranous nephropathy, as well as treatment of this dis

44 (St-Cp) therapy for patients with idiopathic membranous nephropathy at high risk of progression to ES

45 Human membranous nephropathy biopsy samples showed podocyte st

46 - was induced in minimal change disease and membranous nephropathy, but not focal segmental glomerul

47 om such deposits in patients with idiopathic membranous nephropathy, but not in those with lupus memb

48 A2R is the target of the autoimmune disease, membranous nephropathy, characterised by production of a

49 In experimental membranous nephropathy, complement C5b-9-induces glomeru

50 given sheep anti-Fx1A to induce experimental membranous nephropathy; control rats received normal she

51 r cohort, 15 of 154 patients with idiopathic membranous nephropathy had circulating autoantibodies to

52 A majority of patients with idiopathic membranous nephropathy have antibodies against a conform

53 Up to 80% of patients with idiopathic membranous nephropathy have non-complement-fixing IgG4 a

54 rulosclerosis (HR, 0.80; 95% CI, 0.77-0.82), membranous nephropathy (HR, 0.88; 95% CI, 0.83-0.93), me

55 nephropathy (HRa, 0.74; 95% CI, 0.59-0.92), membranous nephropathy (HRa, 0.47; 95% CI, 0.29-0.75), a

56 ase were primary FSGS, diabetic nephropathy, membranous nephropathy, immunoglobulin A nephropathy, an

57 Most patients with idiopathic membranous nephropathy (IMN) have IgG4 autoantibodies ag

58 1) is the major target antigen in idiopathic membranous nephropathy (iMN).

59 the autoimmune glomerular disease idiopathic membranous nephropathy (IMN).

60 In summary, this case of recurrent membranous nephropathy in a graft suggests that circulat

61 phritis is an experimental model that mimics membranous nephropathy in humans, wherein the glomerular

62 in seven patients, diabetic nephropathy and membranous nephropathy in one patient, and death due to

63 sive Heymann nephritis model of experimental membranous nephropathy in rats.

64 al of 35 patients treated with rituximab for membranous nephropathy in two distinct cohorts.

65 peutic advances for patients with idiopathic membranous nephropathy, including antibody inhibition th

66 immune deposits in patients with idiopathic membranous nephropathy, indicating that PLA(2)R is a maj

67 Membranous nephropathy is a common cause of adult nephro

68 Membranous nephropathy is a common cause of nephrotic sy

69 Membranous nephropathy is a disease that affects the fil

70 Idiopathic membranous nephropathy is an autoimmune disease.

71 pports the emerging evidence that idiopathic membranous nephropathy is an autoimmune disease.

72 Membranous nephropathy is characterised by the depositio

73 It is concluded that hypofiltration in membranous nephropathy is the consequence of a biphasic

74 A third distinct type, membranous nephropathy, is rare in children.

75 Membranous nephropathy leads to end-stage renal disease

76 Patients with lupus membranous nephropathy (LMN) are at substantial long-ter

77 d decline in renal function in patients with membranous nephropathy may be due to renal vein thrombos

78 actors, compared with IgAN (referent), FSGS, membranous nephropathy, membranoproliferative GN, lupus

79 ed as a surrogate for long-term prognosis in membranous nephropathy (MGN), variability in proteinuria

80 D7A) is a target antigen identified in adult membranous nephropathy (MN) along with the major antigen

81 Absent a remission of proteinuria, primary membranous nephropathy (MN) can lead to ESRD over many y

82 Membranous nephropathy (MN) can recur in kidney allograf

83 he Heymann nephritis (HN) rat model of human membranous nephropathy (MN) have shown that IgG antibodi

84 fies a new antigen responsible for secondary membranous nephropathy (MN) in a patient with mucopolysa

85 Membranous nephropathy (MN) is a common cause of nephrot

86 Membranous nephropathy (MN) is a leading cause of nephro

87 Primary membranous nephropathy (MN) is an autoimmune disease mai

88 Membranous nephropathy (MN) is the most common cause of

89 Membranous nephropathy (MN) is the most common cause of

90 As recently as 2002, most cases of primary membranous nephropathy (MN), a relatively common cause o

91 A) are the two major autoantigens in primary membranous nephropathy (MN), and define two molecular su

92 ssion in two-thirds of patients with primary membranous nephropathy (MN), even after other treatments

93 is (FSGS), minimal change disease (MCD), and membranous nephropathy (MN), may respond well to cyclosp

94 s a target for autoimmunity in patients with membranous nephropathy (MN).

95 erosis [FSGS], minimal-change disease [MCD], membranous nephropathy [MNP], lupus nephritis [LN], and

96 vs IgAN, ranged from 0.49 for DN to 0.92 for membranous nephropathy or ADPKD) than by lower rates of

97 and nephrotic syndrome caused by idiopathic membranous nephropathy or focal segmental glomeruloscler

98 s from patients with idiopathic or secondary membranous nephropathy or other proteinuric or autoimmun

99 s in 32 patients with FSGS, lupus nephritis, membranous nephropathy, or diabetic nephropathy.

100 20 patients with minimal change disease and membranous nephropathy (P < 0.01).

101 In a rat model of experimental membranous nephropathy (passive Heymann nephritis (PHN))

102 ive glomerulonephritis, IgA nephropathy, and membranous nephropathy), patients with systemic lupus er

103 serum samples from patients with idiopathic membranous nephropathy, patients with other glomerular d

104 Randomized trials of rituximab in primary membranous nephropathy (PMN) have not been conducted.

105 t ( approximately 70%) patients with primary membranous nephropathy (pMN).

106 correlate with the immunological activity of membranous nephropathy, potentially exhibiting a more ra

107 cohort with anti-PLA2R1-negative idiopathic membranous nephropathy recognized a glomerular protein t

108 Membranous nephropathy recurs in 48% of cases threatenin

109 Membranous nephropathy recurs in approximately 40% of pa

110 Nephrotic syndrome due to membranous nephropathy should be recognized as an idiosy

111 ents (70%) with idiopathic but not secondary membranous nephropathy specifically identified a 185-kD

112 lomerulopathies minimal-change nephrosis and membranous nephropathy, there is an increase in Shp2 pho

113 use of immunosuppressive drugs in idiopathic membranous nephropathy to patients at the highest risk o

114 of immune deposit formation in experimental membranous nephropathy to the role of a microRNA in FSGS

115 n nephritis, a complement-dependent model of membranous nephropathy, was examined.

116 with a nephrotic syndrome and biopsy-proven membranous nephropathy were administered a 3 to 6-month

117 while taking an NSAID and if other causes of membranous nephropathy were excluded and a rapid remissi

118 tibodies in serum samples from patients with membranous nephropathy were mainly IgG4, the predominant

119 were serially evaluated in 15 patients with membranous nephropathy who exhibited relapsing nephrosis

120 We describe a 63-year-old man with membranous nephropathy who underwent a kidney transplant

121 samples from the 74 patients with idiopathic membranous nephropathy who were seropositive for anti-PL

122 pholipase A(2) receptor-associated recurrent membranous nephropathy with circulating anti-Phospholipa

123 s renal function in patients with idiopathic membranous nephropathy with declining renal function.

124 a kidney transplant and developed recurrent membranous nephropathy with fine granular co-localizatio

125 y in this cohort of patients with idiopathic membranous nephropathy yielded favorable outcomes while